MDT

87.75

+0.22%↑

114.9

+0.58%↑

VEEV

148.45

-7.44%↓

HQY

81.99

-1.44%↓

TLRY

6.73

+1.2%↑

MDT

87.75

+0.22%↑

114.9

+0.58%↑

VEEV

148.45

-7.44%↓

HQY

81.99

-1.44%↓

TLRY

6.73

+1.2%↑

MDT

87.75

+0.22%↑

114.9

+0.58%↑

VEEV

148.45

-7.44%↓

HQY

81.99

-1.44%↓

TLRY

6.73

+1.2%↑

MDT

87.75

+0.22%↑

114.9

+0.58%↑

VEEV

148.45

-7.44%↓

HQY

81.99

-1.44%↓

TLRY

6.73

+1.2%↑

MDT

87.75

+0.22%↑

114.9

+0.58%↑

VEEV

148.45

-7.44%↓

HQY

81.99

-1.44%↓

TLRY

6.73

+1.2%↑

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Отворен

1.35 0.75

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.32

Максимум

1.3599999999999999

Ключови измерители
By Trading Economics
Приходи	2.7M -24M
EPS	-0.354
Служители	49
EBITDA	-5.3M -28M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+103.82% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-5K 81M
Предишно отваряне	0.6
Предишно затваряне	1.35

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10.04.2026 г., 00:00 ч. UTC

Значими събития в новините

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9.04.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9.04.2026 г., 23:14 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.04.2026 г., 23:07 ч. UTC

Пазарно говорене

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9.04.2026 г., 22:54 ч. UTC

Пазарно говорене

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9.04.2026 г., 22:31 ч. UTC

Значими събития в новините

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9.04.2026 г., 20:57 ч. UTC

Значими събития в новините

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9.04.2026 г., 20:55 ч. UTC

Печалби

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

9.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.04.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9.04.2026 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Rowan Digital Infrastructure Announces Strategic Recapitalization

9.04.2026 г., 20:25 ч. UTC

Придобивния, сливания и поглъщания

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9.04.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.04.2026 г., 19:30 ч. UTC

Значими събития в новините

How Digital Currencies Have Helped Iran -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

103.82% нагоре

12-месечна прогноза

Среден 2.67 USD 103.82%

Висок 3 USD

Нисък 2 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.